PF3D7_0802200

PF3D7_0802200 (1-CysPxn/Pf1-Cys-Prx) is a cytoplasmic peroxiredoxin of Plasmodium falciparum that functions in antioxidant defense against metabolism-derived reactive oxygen species during intraerythrocytic development (PMID:15710548, PMID:15794764, PMID:21203490). Its protein expression is elevated during the trophozoite and early schizont stages, coinciding with the period of peak heme-digestion activity (PMID:15710548), and this stage-specificity is set transcriptionally by a trophozoite/schizont-specific cis-acting enhancer in the 5' region that is bound by stage-specific DNA-binding proteins, together with PfGCN5-dependent histone acetylation of the same region (PMID:18692528). Biochemically, recombinant 1-CysPxn binds ferriprotoporphyrin IX (heme/FP) directly at cytosolic pH, competes with glutathione for FP, limits GSH-mediated FP degradation and the accompanying iron release, and protects target proteins such as glutamine synthetase and enolase from iron-derived oxidative inactivation (PMID:15794764). Despite these in vitro protective activities, genetic knockout of the gene does not sensitize parasites to ROS, RNS, chloroquine, or heat stress under standard conditions, indicating that its cytoplasmic function is dispensable and distinct from the heat-stress-protective PfTPx-1 (PMID:23201565). Orthologs in P. yoelii, P. vivax, and P. knowlesi share cytoplasmic localization and mixed-function-oxidation antioxidant activity (PMID:14572508, PMID:23178658), and in P. berghei ookinetes 1-Cys Prx is induced by ROS and expressed earlier upon loss of TPx-1, indicating partial functional compensation between the two peroxiredoxins (PMID:23382676).

1. 2000 Medium

   Establishing the molecular identity of the gene was the first step: cloning defined 1-CysPxn as a distinct peroxiredoxin-family peroxidase in P. falciparum rather than an uncharacterized ORF.

   Evidence Molecular cloning and biochemical characterization in P. falciparum

   PMID:10960175

   Open questions at the time

   • No functional or localization data at this stage
   • Enzymatic substrate not defined
2. 2003 Medium

   Work in the rodent malaria ortholog first tied a 1-Cys Prx to stage-specific trophozoite cytoplasmic expression and demonstrable antioxidant protection, framing the family's blood-stage role.

   Evidence Immunofluorescence and mixed-function oxidation enzyme-protection assay with recombinant P. yoelii protein

   PMID:14572508

   Open questions at the time

   • Rodent ortholog, not PF3D7_0802200 directly
   • No in vivo requirement tested
3. 2005 High

   Two 2005 studies resolved where and when the P. falciparum protein acts and what it does: cytoplasmic, trophozoite/schizont-elevated expression, plus direct heme binding, competition with GSH, and protection of proteins from iron-derived ROS.

   Evidence Western blot, confocal microscopy and qRT-PCR for expression [#1]; FP-agarose pulldown, FP-degradation and enzyme-protection assays with recombinant protein [#2]

   PMID:15710548 PMID:15794764

   Open questions at the time

   • Peroxidase reaction cycle and redox partner not defined in vitro
   • In vivo relevance of heme binding untested
4. 2008 High

   The mechanistic basis of the observed stage-specific expression was defined: a 5' cis-enhancer bound by stage-specific factors plus PfGCN5-dependent histone acetylation drive trophozoite/schizont transcription.

   Evidence Reporter assays, EMSA, DNase I footprinting, and ChIP in P. falciparum

   PMID:18692528

   Open questions at the time

   • Identity of the stage-specific DNA-binding factors not established
   • Link between transcriptional control and antioxidant demand not directly tested
5. 2010 Medium

   Systematic redox-compartment mapping confirmed exclusive cytoplasmic targeting and showed the protein does not use alternative translation initiation for dual localization, unlike some other Plasmodium redox proteins.

   Evidence Fluorescence-based subcellular localization within a genome-scale redox mapping study in P. falciparum

   PMID:21203490

   Open questions at the time

   • Does not address functional consequence of localization
6. 2012 Medium

   Genetic knockout tested whether the biochemical antioxidant activity is physiologically required, showing the gene is dispensable for resistance to ROS, RNS, chloroquine, and heat stress and functionally distinct from PfTPx-1.

   Evidence Gene knockout and phenotypic stress-sensitivity assays in P. falciparum

   PMID:23201565

   Open questions at the time

   • Redundancy with other peroxiredoxins under standard conditions not excluded
   • Phenotypes under non-standard or in vivo conditions untested
7. 2012 Medium

   Orthologs from P. vivax and P. knowlesi extended the cytoplasmic, mixed-function-oxidation antioxidant activity across human-infective Plasmodium species, indicating conservation.

   Evidence Heterologous expression, mixed-function oxidation assay, and immunofluorescence in P. vivax and P. knowlesi

   PMID:23178658

   Open questions at the time

   • Ortholog data, not PF3D7_0802200 itself
   • No knockout in these species
8. 2013 High

   Reciprocal genetics in the P. berghei ookinete revealed functional interplay: 1-Cys Prx is ROS-inducible and is expressed earlier when TPx-1 is deleted, indicating partial compensation between the two peroxiredoxins.

   Evidence qRT-PCR, confocal immunofluorescence, and tpx-1 knockout comparison in P. berghei ookinetes

   PMID:23382676

   Open questions at the time

   • Compensation shown at expression level, not by rescue of a knockout phenotype
   • Ookinete-stage finding; blood-stage compensation not tested

• The physiological substrate, redox cycling partner, and the condition under which 1-CysPxn's antioxidant/heme-binding activity becomes essential remain undefined.
• No physiological reducing substrate/partner identified
• Condition of non-redundancy unknown
• Structural basis of heme binding not determined